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Abstract: This is a cross-sectional study of 15 aviremic chronic
HIV-infected children revealing no differences in immune activation
(IA; HLA-DRþCD38þ CD4þ and CD8þ T cells, and sCD14) and
microbial translocation (MT; lipopolysaccharides (LPS) and 16S
rDNA) among HIV-infected patients under combined antiretroviral
treatment (cART; n¼ 10) or ritonavir-boosted protease inhibitor mono-
therapy (mtPI/rtv; n¼ 5). In both cases, IA and MT were lower in
healthy control children (n¼ 32). This observational study suggests that
ritonavir boosted protease inhibitor monotherapy (mtPI/rtv) is not
associated with an increased state of IA or MT as compared with
children receiving cART.
(Medicine 94(11):e521)
INTRODUCTION
C hronic HIV infection, even under long-term suppressivecombined antiretroviral therapy (cART), is associated with
persistent immune activation (IA), the latter contributing to
impaired immunological reconstitution,1 higher mortalityortuny, MD, PhD, , PhD,
rte´s, MD, PhD
effective and safe alternative for simplification in selected
patients with HIV infection in adults5; however, the experience
with mtPI/rtv in children is very limited.6 To date, inflam-
mation, microbial translocation (MT), and IA in HIV-infected
children receiving mtPI/rtv have not been studied. Thus, the aim
of the study was to compare inflammation, MT, and IA in HIV-
infected children receiving mtPI/rtv with those on cART,
thereby analyzing whether mtPI/rtv therapy is or is not associ-
ated with increased immunological, bacterial, and virological
biomarkers compared with the later.
METHODOLOGY
This was a cross-sectional study of aviremic chronically
HIV-infected children between November 2011 and May 2012
from a tertiary-care pediatric hospital in Spain. Inclusion
criteria to switch from cART to mtPI/rtv included viral sup-
pression (HIV-RNA levels< 50 copies/ml) for at least 6 months
while on cART, lack of a history of prior virological failure and
no genotypic resistance in protease gene, as well as simplifica-
tion to reduce nucleoside analogues and non-analogues toxicity
in children who need long term antiretroviral therapy. Children
were classified according to their antiretroviral regimen: cART
vs. mtPI/rtv.
Additionally, a control group of healthy patients, matched
for age, sex, and race, referred for routine minor surgery, was
used. The study was approved by the local ethical Committee
and conducted according to the Declaration of Helsinki. Before
inclusion, informed consent from parents or legal guardians was
obtained for all patients.
Plasma HIV viremia was assessed by quantitative poly-
merase chain reaction (PCR) (COBAS AmpliPrep/COBAS
TaqMan HIV-1 Test, version 2.0, Roche Diagnostic System,
Branchburg, NJ, USA). Soluble serum inflammation markers
including ultrasensitive C-reactive protein (uCRP), D-dimer,
and b-2-microglobulin levels were routinely determined by
the hospital Department of Biochemistry.
Cellular IA was measured as the simultaneous expression
of HLA-DR and CD38 in both CD4þ and CD8þ T cells by flow
cytometry (FACSCalibur flow cytometer and CellQuest soft-
ware, BD Biosciences, Madrid, Spain). Systemic IA was
assessed by plasma sCD14 levels (marker of monocyte acti-
vation), using the Human sCD14 Quantikine ELISA kit (R&D
Systems, Abingdon, UK), following manufacturer’s instruc-
tions. MT was assessed through plasma lipopolysaccharidesLimulus amebocyte lysate chromogenic
, Basel, Switzerland), according to the
mendations. Additionally, plasma 16S
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rDNA levels were measured, determined by quantitative poly-
merase chain reaction (PCR) from 200mL of plasma, as pre-
viously described.7 Chosen biomarkers were adapted from
previous publications in this field.8–11
Quantitative variables were summarized using medians
and interquartile ranges, whereas absolute values and relative
frequencies were used for qualitative variables. The populations
were studied to know whether they followed or not a normal
distribution. Normally distributed variables were compared
with the Student t test or analysis of variance. For non-normally
distributed variables, nonparametric tests (the Mann–Whitney
U and Kruskal–Wallis H tests) were used to compare the
medians between the different groups. Correlations were
assessed by means of the Pearson or Spearman tests as adequate.
The differences were considered statistically significant for P
values <0.05. The statistical analyses were performed using
SPSS software (v. 19.0, Chicago, IL, USA).
RESULTS
A total of 47 children were enrolled in the study, including
15 HIV-infected children (10 children on cART and 5 children
on mtPI/rtv) and 32 healthy controls. Patients on monotherapy
were switched to ritonavir-boosted lopinavir/r (mLPV/rtv) in
4 cases and atazanavir (mATZ/rtv) in 1 case at standard
dosages. In the rest of HIV-infected patients, cART regimens
were as follows: 8 children received 2 nucleoside reverse
transcriptase inhibitor (NRTI), plus a ritonavir-boosted protease
inhibitor (PI/rtv) in 5 and a non-nucleoside reverse transcriptase
inhibitor (NNRTI) in 3 children. One child was treated with a
NRTI/NNRTI/r/PI regimen and 1 patient with a NRTI/integrase
inhibitor (INI) bi-therapy.
As shown in Table 1, no differences regarding clinical
parameters, such as sex, age, or body mass index were observed
between healthy controls and HIV-infected children, either on
cART or mtPI/rtv. Moreover, no differences were found in the
time on ART and on viral suppression between HIV-infected
children receiving cART or mtPI/rtv. Children in the mono-
Falcon-Neyra et altherapy group were on this simplification strategy for a median
of 28 months (interquartile range [IQR]: 18.4–29.9 months)
prior to the enrollment on this study. None of the HIV-infected
TABLE 1. Clinical and Immunovirological Characteristics of the E
Patients on cART and HIV-infected Patients on mtPI/rtv
Healthy Controls
(n¼ 32)
HIVþ
(n¼
Age, y, M (IQR) 9.0 (6.8–13.4) 12.0 (12.
Sex (male), n (%) 13 (38.2) 4 (40.0)
BMI, M (IQR) 16.5 (15.2–22.4) 18.6 (15.
Total time in ART, mo, M (IQR) — 100.4 (57
Continuous time in ART (months), M (IQR) — 53.4 (51.
Time on viral suppression, mo, M (IQR) — 31.5 (22.
Nadir CD4, cells/mL, M (IQR) — 273 (163
D-Dimers, mg/L, M (IQR) 0.19 (0.19–0.24) 0.21 (0.1
b-2-microglobulin, mg/L, M (IQR) 1.60 (1.40–1.90) 1.60 (1.5
uCRP, mg/L, M (IQR) 0.6 (0.4–1.3) 5.83 (1.6
CD4þ T cell counts, cells/mL, M (IQR) 1149 (789–1396) 745 (574
CD8þ T cell counts, cells/mL, M (IQR) 661 (517–873) 817 (539
Ratio CD4:CD8, M (IQR) 1.6 (1.4–2.0) 1.1 (0.6–
BMI¼ body mass index, cART¼ combined antiretroviral treatment, IQ
rtv¼ ritonavir-boosted protease inhibitor monotherapy, n¼ number of patie
2 | www.md-journal.comchildren suffered from HCV/HBV co-infection and CDC stage
did not differ within the 2 HIV groups (data not shown).
Regarding inflammation markers, no differences were
found between HIV-infected patients on cART and mtPI/rtv
in the median (IQR) levels of D-dimers, b-2-microglobulin, or
uCRP. In addition, similar results were observed when healthy
control and HIV-infected children were compared regarding
D-dimer and b-2-microglobulin, though HIV-infected children
showed higher uCRP levels (Table 1).
As expected, healthy controls showed higher CD4þ T-cell
counts and CD4:CD8 ratios (Table 1), but lower IA and MT
profiles compared with HIV-infected children (Figure 1A–E).
Among HIV-infected patients, similar CD4þ (745 vs
812 cells/mL, P¼ 0.624) and CD8þ T-cells counts (817 vs
790 cells/mL, P¼ 0.859) were found in cART- and mtPI/rtv-
treated children, and thus similar CD4:CD8 ratio (1.1 vs 1.2,
P¼ 0.440).
Similarly, no differences regarding IA were found in both
CD4þ (6.3% vs 7.5%, ¼ 0.221) and CD8þ T cells (7.3% vs
6.8%, P¼ 0.733) among children on cART or mtPI/rtv
(Figure 1A and B). MT was similar between children on cART
and mtPI/rtv assessed by the levels of 16S rDNA (6.3 vs 6.0 log
copies/mL, P¼ 0.221) and LPS (74.5 vs 76.1 pg/mL, P¼ 0.460;
Figure 1C and D). Finally, plasma sCD14 levels were also
similar between both groups of HIV-infected patients (1417 vs
1579 ng/mL, P¼ 0.165; Figure 1E).
DISCUSSION
Although few studies have focused on inflammation, MT,
and IA profiles in HIV-infected children and its potential role on
non-AIDS-defining illnesses,12,13 no data exist in children
receiving mtPI/rtv. Thus, we designed this study, in which
higher levels of biomarkers of IA and MT in chronic HIV-
infected children compared with healthy controls were observed
as previously reported.12,13 However, importantly, we did not
find differences in inflammation, IA, or MT between aviremic
HIV-infected children receiving either cART or mtPI/rtv.
Medicine  Volume 94, Number 11, March 2015Our observation is supported by recently published data
from adult patients receiving mtPI/rtv or cART, demonstrating
no differences in the levels of inflammatory and procoagulant
nrolled Children, Classified as Healthy Controls, HIV-infected
cART
10)
HIVþ mtPI/rtv
(n¼ 5)
Controls vs
HIVþ P Value
cART vs
mtPI/rtv P Value
9–15.2) 10.8 (10.8–12.0) 0.424 0.280
2 (40.0) 0.989 0.830
4–22.8) 19.3 (19.1–21.4) 0.310 0.580
.6–128.2) 127.8 (80.8–128.8) — 0.206
8–92.1) 127.8 (80.8–128.8) — 0.250
7–55.7) 67.0 (33.0–80.0) — 0.250
–420) 275 (213–463) — 0.680
9–0.41) 0.25 (0.20–0.29) 0.250 0.953
8–1.75) 1.60 (1.55–1.69) 0.655 0.440
9–15.80) 0.97 (0.63–2.64) 0.024 0.440
–999) 812 (798–997) 0.032 0.624
–998) 790 (572–876) 0.349 0.859
1.4) 1.2 (1.1–1.3) 0.017 0.440
R¼ interquartile range, LPS¼ lipopolysaccharide, M¼median, mtPI/
nts.
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FIGURE 1. Immune activation (A,B) and microbial translocation (C-E) profiles of HIV negative children (HIV-) and HIVþ children receiving
ritonavir boosted protease inhibitor monotherapy (mtPI/rtv) or combined antiretroviral therapy (cART). M¼Median, IQR¼ interquartile
range.
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markers including CRP, interleukin-6, fibrinogen and
D-dimer.14 Furthermore, in a 2-year follow-up study of adult
patients who were switched from cART to mtPI/rtv, cellular IA
(measured as the expression of HLA-DRþCD38þ on CD4þ and
CD8þ T cells) and systemic IA (measured as soluble CD14
and D-dimer) markers did not change among patients
remaining on viral suppression along follow-up.8 Owing to a
higher risk of viral rebound, the International Antiviral
Society-USA Panel does not recommend the use of mtPI/rtv
in adult patients when other options are available.15 Although
preliminary results of the PIVOT (Protease Inhibitor mono-
therapy Versus Ongoing Triple-therapy in the long-term man-
agement of HIV infection) Trial study revealed a viral load
rebound rate of 35% using mtPI/rtv,16 the clinical relevance of
viral load rebounds remains to be established as ‘‘blip
episodes’’ and intermittent viremia have been shown not to
affect the cellular HIV reservoir dynamic in patients receiving
mtPI/rtv and were not associated with accumulation of new
resistant mutations.5,17
An important limitation of this observational study is the
small sample size. However, to date, there are few data on
children receiving mtPI/rtv therapy and no published data on
immune activation and/or inflammation in this particular group
of patients. In this context, our observation is new and probably
reassuring, although the presented results need to be confirmed
with larger prospective clinical studies. As cART has been and
continues to be the gold standard in the management of HIV-
infected children, mtPI/rtv therapy is generally not recom-
mended in children and should only be considered in very
selected children under exceptional circumstances. It is for
these reasons that sample size is and will continue to be low.
Therefore, a multicenter study approach is required to further
evaluate our observation of mtPI/rtv not to be associated with
increased IA or inflammation compared with cART. The
clinical relevance of our observation is potentially important,
since safety and effectiveness of simplification strategies based
on mtPI/rtv as an alternative in very selected children are
paramount.
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